Literature DB >> 12672830

Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.

Anne-Sofie Schrohl1, Ib Jarle Christensen, Anders N Pedersen, Vibeke Jensen, Henning Mouridsen, Gillian Murphy, John A Foekens, Nils Brunner, Mads Nikolaj Holten-Andersen.   

Abstract

The purpose of this study was to investigate the association between tumor tissue levels of total tissue inhibitor of metalloproteinases-1 (TIMP-1) and prognosis in patients with primary breast cancer and to analyze whether measurement of TIMP-1 in tumor extracts added prognostic information to that obtained from measurements of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 (PAI-1). An established sandwich enzyme-linked immunosorbent assay was thoroughly validated for the measurement of total TIMP-1 in tumor tissue extracts and used to determine levels of total TIMP-1 in 341 detergent-extracted tumor tissue samples from patients with primary breast cancer. The median age of the patients was 56 years (range, 29-75 years), and 164 were lymph node-negative, and 177 were lymph node-positive. The median follow-up time of the patients was 8.5 years (range, 7.3-11.3 years), and during follow-up 153 patients experienced recurrence of disease, and 136 patients died. In univariate survival analysis, we found a significant association between tumor tissue TIMP-1 level and both shorter recurrence-free survival (p = 0.0004) and shorter overall survival (p = 0.03). In multivariate survival analysis, higher tumor tissue TIMP-1 levels significantly and independently predicted shorter recurrence-free survival (p < 0.05, hazard ratios >1, comparing quartiles II-IV with I). In addition, we found that measurement of TIMP-1 levels added prognostic information to that obtained from measurement of PAI-1. In conclusion, high levels of TIMP-1 in tumor tissue extracts are significantly associated with a poor prognosis in patients with primary breast cancer. Furthermore TIMP-1 adds prognostic information to that obtained from PAI-1. However, further validation in independent data sets is needed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672830     DOI: 10.1074/mcp.M300019-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  17 in total

1.  Effects of dietary fat on spontaneous metastasis of Lewis lung carcinoma in mice.

Authors:  Lin Yan; Lana C DeMars
Journal:  Clin Exp Metastasis       Date:  2010-08-10       Impact factor: 5.150

2.  Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation.

Authors:  Tatiana I Ricca; Gangning Liang; Ana Paula M Suenaga; Sang W Han; Peter A Jones; Miriam G Jasiulionis
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

Review 3.  Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response.

Authors:  Matthew David Hale; Jeremy David Hayden; Heike Irmgard Grabsch
Journal:  Cell Oncol (Dordr)       Date:  2013-03-14       Impact factor: 6.730

4.  Identification of alternatively spliced TIMP-1 mRNA in cancer cell lines and colon cancer tissue.

Authors:  P A Usher; A M Sieuwerts; A Bartels; U Lademann; H J Nielsen; L Holten-Andersen; J A Foekens; N Brünner; H Offenberg
Journal:  Mol Oncol       Date:  2007-05-21       Impact factor: 6.603

Review 5.  Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities.

Authors:  William G Stetler-Stevenson
Journal:  Sci Signal       Date:  2008-07-08       Impact factor: 8.192

6.  Immunohistochemical expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in invasive breast carcinoma.

Authors:  Suada Kuskunović; Svjetlana Radović; Mirsad Dorić; Ajna Hukić; Mirsad Babić; Ivana Tomić; Ivan Selak
Journal:  Bosn J Basic Med Sci       Date:  2009-05       Impact factor: 3.363

7.  Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer.

Authors:  Karin Söderlund Leifler; Susanne Svensson; Annelie Abrahamsson; Christina Bendrik; Jennifer Robertson; Jack Gauldie; Anna-Karin Olsson; Charlotta Dabrosin
Journal:  J Immunol       Date:  2013-03-15       Impact factor: 5.422

8.  Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer.

Authors:  José M del Casar; Guillermo Carreño; Luis O González; Sara Junquera; Salomé González-Reyes; José M González; Miguel Bongera; Antonio M Merino; Francisco J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-30       Impact factor: 4.553

9.  Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.

Authors:  Rita C S Figueira; Luciana R Gomes; João S Neto; Fabricio C Silva; Ismael D C G Silva; Mari C Sogayar
Journal:  BMC Cancer       Date:  2009-01-14       Impact factor: 4.430

10.  Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study.

Authors:  Anne-Sofie Schrohl; Maxime P Look; Marion E Meijer-van Gelder; John A Foekens; Nils Brünner
Journal:  BMC Cancer       Date:  2009-09-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.